organization · Reporting owner
Wilmslow Estates Ltd
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Ocugen, Inc.
Report date February 08, 2019 · Filed February 11, 2019
Section 16 reporting ended · disclosed 2019-02-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,258,859 |
Ending reported balance
After 2019-02-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-02-08 · Exercise / conversion · Acquired 403,845 · Balance 4,014,415 F1: The per share exercise price of each Common Stock Warrant was re-priced to $0.01 pursuant to a warrant exercise agreement entered into with the Issuer on February 8, 2019. Row 2 · 2019-02-08 · Exercise / conversion · Acquired 1,244,444 · Balance 5,258,859 F1: The per share exercise price of each Common Stock Warrant was re-priced to $0.01 pursuant to a warrant exercise agreement entered into with the Issuer on February 8, 2019. |
| Common Stock Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.01 · Expires 2023-10-10 | Direct | 0 |
Reported balance
After 2019-02-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-02-08 · Exercise / conversion · Acquired 403,845 · Balance 0 F1: The per share exercise price of each Common Stock Warrant was re-priced to $0.01 pursuant to a warrant exercise agreement entered into with the Issuer on February 8, 2019. |
| Common Stock Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.01 · Expires 2021-11-22 | Direct | 0 |
Reported balance
After 2019-02-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-02-08 · Exercise / conversion · Acquired 1,244,444 · Balance 0 F1: The per share exercise price of each Common Stock Warrant was re-priced to $0.01 pursuant to a warrant exercise agreement entered into with the Issuer on February 8, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The per share exercise price of each Common Stock Warrant was re-priced to $0.01 pursuant to a warrant exercise agreement entered into with the Issuer on February 8, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 08, 2019 Filed Feb 11, 2019 21:27 UTC | Ocugen, Inc. HSGX · Entity 5550 | Exercise / conversionCommon Stock Warrant (Right to Buy) · Derivative | 1,244,444 | Not disclosed Strike: $0.01 | Not disclosed |
DisclosureSEC source: 0000899243-19-003147 · doc4.xml · derivative · entry 4 Wilmslow Estates Ltd · CIK 0001626777 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,244,444 shares Expires 2021-11-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The per share exercise price of each Common Stock Warrant was re-priced to $0.01 pursuant to a warrant exercise agreement entered into with the Issuer on February 8, 2019. Read SEC document |
| February 08, 2019 Filed Feb 11, 2019 21:27 UTC | Ocugen, Inc. HSGX · Entity 5550 | Exercise / conversionCommon Stock Warrant (Right to Buy) · Derivative | 403,845 | Not disclosed Strike: $0.01 | Not disclosed |
DisclosureSEC source: 0000899243-19-003147 · doc4.xml · derivative · entry 3 Wilmslow Estates Ltd · CIK 0001626777 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 403,845 shares Expires 2023-10-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The per share exercise price of each Common Stock Warrant was re-priced to $0.01 pursuant to a warrant exercise agreement entered into with the Issuer on February 8, 2019. Read SEC document |
| February 08, 2019 Filed Feb 11, 2019 21:27 UTC | Ocugen, Inc. HSGX · Entity 5550 | Exercise / conversionCommon Stock | 1,244,444 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-003147 · doc4.xml · nonDerivative · entry 2 Wilmslow Estates Ltd · CIK 0001626777 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,258,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The per share exercise price of each Common Stock Warrant was re-priced to $0.01 pursuant to a warrant exercise agreement entered into with the Issuer on February 8, 2019. Read SEC document |
| February 08, 2019 Filed Feb 11, 2019 21:27 UTC | Ocugen, Inc. HSGX · Entity 5550 | Exercise / conversionCommon Stock | 403,845 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-003147 · doc4.xml · nonDerivative · entry 1 Wilmslow Estates Ltd · CIK 0001626777 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,014,415 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The per share exercise price of each Common Stock Warrant was re-priced to $0.01 pursuant to a warrant exercise agreement entered into with the Issuer on February 8, 2019. Read SEC document |
| October 10, 2018 Filed Oct 11, 2018 20:30 UTC | Ocugen, Inc. HSGX · Entity 5550 | PurchaseCommon Stock Warrant (Right to Buy) · Derivative | 403,845 | Not disclosed Strike: $0.70 | Not disclosed |
DisclosureSEC source: 0000899243-18-026560 · doc4.xml · derivative · entry 2 Wilmslow Estates Ltd · CIK 0001626777 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 403,845 Underlying: Common Stock · 403,845 shares Expires 2023-10-10 F1 · price: The Common Stock and Common Stock Warrants were issued and sold in a fixed combination at a purchase price of $0.65 per unit. Each share of Common Stock is accompanied by a Common Stock Warrant to purchase 0.75 shares of Common Stock, which are exercisable immediately for a period of 5 years from the date of issuance. Read SEC document |
| October 10, 2018 Filed Oct 11, 2018 20:30 UTC | Ocugen, Inc. HSGX · Entity 5550 | PurchaseCommon Stock | 538,460 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-026560 · doc4.xml · nonDerivative · entry 1 Wilmslow Estates Ltd · CIK 0001626777 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,610,570 F1 · price: The Common Stock and Common Stock Warrants were issued and sold in a fixed combination at a purchase price of $0.65 per unit. Each share of Common Stock is accompanied by a Common Stock Warrant to purchase 0.75 shares of Common Stock, which are exercisable immediately for a period of 5 years from the date of issuance. Read SEC document |
| December 02, 2016 Filed Dec 5, 2016 22:00 UTC | Ocugen, Inc. HSGX · Entity 5550 | ConversionSeries A Convertible Preferred Stock · Derivative | 2,242.7528 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-16-034929 · doc4.xml · derivative · entry 2 Wilmslow Estates Ltd · CIK 0001626777 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 996,779 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All outstanding shares of the Issuer's Series A Convertible Preferred Stock converted on a 1:444.444444 basis into shares of the Issuer's Common Stock. These shares have no expiration date. F1 · shares: All outstanding shares of the Issuer's Series A Convertible Preferred Stock converted on a 1:444.444444 basis into shares of the Issuer's Common Stock. These shares have no expiration date. F1 · derivative.exercise_date: All outstanding shares of the Issuer's Series A Convertible Preferred Stock converted on a 1:444.444444 basis into shares of the Issuer's Common Stock. These shares have no expiration date. F1 · derivative.expiration_date: All outstanding shares of the Issuer's Series A Convertible Preferred Stock converted on a 1:444.444444 basis into shares of the Issuer's Common Stock. These shares have no expiration date. F1 · derivative.underlying_shares: All outstanding shares of the Issuer's Series A Convertible Preferred Stock converted on a 1:444.444444 basis into shares of the Issuer's Common Stock. These shares have no expiration date. Read SEC document |
| December 02, 2016 Filed Dec 5, 2016 22:00 UTC | Ocugen, Inc. HSGX · Entity 5550 | ConversionCommon Stock | 996,779 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-16-034929 · doc4.xml · nonDerivative · entry 1 Wilmslow Estates Ltd · CIK 0001626777 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,072,110 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: All outstanding shares of the Issuer's Series A Convertible Preferred Stock converted on a 1:444.444444 basis into shares of the Issuer's Common Stock. These shares have no expiration date. F1 · price: All outstanding shares of the Issuer's Series A Convertible Preferred Stock converted on a 1:444.444444 basis into shares of the Issuer's Common Stock. These shares have no expiration date. Read SEC document |
| September 29, 2016 Filed Oct 3, 2016 21:15 UTC | Ocugen, Inc. HSGX · Entity 5550 | GrantCommon Stock Warrant (Right to Buy) · Derivative | 1,244,444 | $0.00 Strike: $2.25 | $0.00 |
DisclosureSEC source: 0000899243-16-030576 · doc4.xml · derivative · entry 3 Wilmslow Estates Ltd · CIK 0001626777 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,244,444 shares Expires not disclosed F2 · derivative.exercise_date: The Common Stock Warrant is exercisable at any time on or after the date (the "Initial Exercise Date") that the Issuer's stockholders approve the transactions contemplated by that certain securities purchase agreement dated September 15, 2016 pursuant to which the warrant was issued through the close of business on the five year anniversary of the Initial Exercise Date. F2 · derivative.expiration_date: The Common Stock Warrant is exercisable at any time on or after the date (the "Initial Exercise Date") that the Issuer's stockholders approve the transactions contemplated by that certain securities purchase agreement dated September 15, 2016 pursuant to which the warrant was issued through the close of business on the five year anniversary of the Initial Exercise Date. Read SEC document |
| September 29, 2016 Filed Oct 3, 2016 21:15 UTC | Ocugen, Inc. HSGX · Entity 5550 | GrantSeries A Convertible Preferred Stock · Derivative | 2,242.7528 | $1,000.00 | $2,242,752.80 |
DisclosureSEC source: 0000899243-16-030576 · doc4.xml · derivative · entry 2 Wilmslow Estates Ltd · CIK 0001626777 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 996,779 shares Expires not disclosed F1 · derivative.exercise_price: The shares of Series A Convertible Preferred Stock have a stated value of $1,000 per share and will be convertible into an aggregate of 996,779 shares of the Issuer's Common Stock, subject to certain conditions including the receipt of requisite stockholder approval pursuant to the Certificate of Designation governing the rights, preferences and privileges of the Series A Convertible Preferred Stock. The initial conversion price of $2.25 is subject to appropriate adjustment in the event of a stock split, stock dividend, combination, reclassification or other recapitalization affecting the Issuer's Common Stock. F1 · shares: The shares of Series A Convertible Preferred Stock have a stated value of $1,000 per share and will be convertible into an aggregate of 996,779 shares of the Issuer's Common Stock, subject to certain conditions including the receipt of requisite stockholder approval pursuant to the Certificate of Designation governing the rights, preferences and privileges of the Series A Convertible Preferred Stock. The initial conversion price of $2.25 is subject to appropriate adjustment in the event of a stock split, stock dividend, combination, reclassification or other recapitalization affecting the Issuer's Common Stock. F1 · derivative.exercise_date: The shares of Series A Convertible Preferred Stock have a stated value of $1,000 per share and will be convertible into an aggregate of 996,779 shares of the Issuer's Common Stock, subject to certain conditions including the receipt of requisite stockholder approval pursuant to the Certificate of Designation governing the rights, preferences and privileges of the Series A Convertible Preferred Stock. The initial conversion price of $2.25 is subject to appropriate adjustment in the event of a stock split, stock dividend, combination, reclassification or other recapitalization affecting the Issuer's Common Stock. F1 · derivative.expiration_date: The shares of Series A Convertible Preferred Stock have a stated value of $1,000 per share and will be convertible into an aggregate of 996,779 shares of the Issuer's Common Stock, subject to certain conditions including the receipt of requisite stockholder approval pursuant to the Certificate of Designation governing the rights, preferences and privileges of the Series A Convertible Preferred Stock. The initial conversion price of $2.25 is subject to appropriate adjustment in the event of a stock split, stock dividend, combination, reclassification or other recapitalization affecting the Issuer's Common Stock. F1 · derivative.underlying_shares: The shares of Series A Convertible Preferred Stock have a stated value of $1,000 per share and will be convertible into an aggregate of 996,779 shares of the Issuer's Common Stock, subject to certain conditions including the receipt of requisite stockholder approval pursuant to the Certificate of Designation governing the rights, preferences and privileges of the Series A Convertible Preferred Stock. The initial conversion price of $2.25 is subject to appropriate adjustment in the event of a stock split, stock dividend, combination, reclassification or other recapitalization affecting the Issuer's Common Stock. Read SEC document |
| September 29, 2016 Filed Oct 3, 2016 21:15 UTC | Ocugen, Inc. HSGX · Entity 5550 | GrantCommon Stock | 247,665 | $2.25 | $557,246.25 |
DisclosureSEC source: 0000899243-16-030576 · doc4.xml · nonDerivative · entry 1 Wilmslow Estates Ltd · CIK 0001626777 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,075,331 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.